Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Ingelheim Buys Cellomics Automated Cell Imaging Technology

NEW YORK, Aug. 3 – Cellomics has sold its ArrayScan HCS system for imaging cells to Boehringer Ingelheim Pharmaceuticals, Cellomics said on Friday.

The giant German pharma company will use the system to automate its drug-discovery process, the company said in a statement.

Financial details were not disclosed.

The HCS system analyzes how potential drugs affect cells by automatically imaging whether cellular probes fluoresce. The system, which Cellomics said has been placed in nine of the top 10 pharmaceutical companies in the world, is compatible with both 96 and 384 well microtitre plates.

In addition to ArrayScan, Cellomics is also developing other screening and bioinformatics products for cell analysis.  

“Cellomics is very proud to have placed an ArrayScan HCS system in the lab or such a well-respected company,” Cellomics Vice President for Sales Paul Kinnon said in the statement.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.